Скачать или смотреть China 2019 - China's Biotech Revolution

Last year, 30% of all investments into US biotech start-ups came from Chinese venture funds; the Hong Kong Stock Exchange issued its first pre-commercial biotech IPOs; and US regulators for the first time approved a new cancer drug developed by a Chinese company. How will the rise of China as a biotech powerhouse affect the global biotech industry?

This session was developed in partnership with Scientific American.

Speakers:
Cong Yali, Professor; Dean, Department of Medical Ethics and Health Law, Peking University, People's Republic of China.
Xu Xun, President, Research, BGI, People's Republic of China.
Jackson Zhu Weiyan, Chief Executive Officer and Founder, My Bio-Med, People's Republic of China.

Moderated by:
Mariette DiChristina, Editor-in-Chief, Scientific American, USA.

http://www.weforum.org/